AK104 for Recurrent or Metastatic Vulvar Cancer
ConditionVulvar Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-80
SponsorAkeso
About this trial
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- AK104
- AK104+ Paclitaxel+Cisplatin or Carboplatin
Treatment groups
20 Participants
are divided into 2 treatment groupsLocations
6Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital350000, FuzhouFujian, China
Sun Yant-Sen Memorial Hospital510000, GuangzhouGuangdong, China
The Fourth Hospital of Hebei Medical University050000, ShijiangzhuangHebei, China
Liaoning Cancer Hospital & Insitut110042, ShenyangLiaoning, China
Sponsors and collaborators
Akeso
Lead sponsor
Source ClinicalTrials.gov